Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men

Journal of General Internal Medicine

Volumn 28, Issue 11, 2013, Pages 1483-1491

  Pignone, Michael ^a,d   Earnshaw, Stephanie ^b   McDade, Cheryl ^b   Pletcher, Mark J ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

aspirin; cancer mortality; coronary heart disease; guideline based intervention; primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; HEART INFARCTION; HIDDEN MARKOV MODEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION; SUDDEN CARDIAC DEATH; TREATMENT DURATION; TREATMENT OUTCOME;

ASPIRIN; COST-BENEFIT ANALYSIS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NEOPLASMS; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 84885952321     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2465-6     Document Type: Article

References (43)

1. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849- 60.
2. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: asex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306-13. Erratum in: JAMA. 2006 May 3;295(17):2002. PubMed PMID:16418466.
3. Hernandez-Diaz S, Garcia Rodriquez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.
4. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307(21):2286-94.
5. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
6. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(1):115-24. e2. Review. PubMed PMID: 21742097.
7. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621-9. Epub 2011 May 17. PubMed PMID: 21592450.
8. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85(3):265-271.
9. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209-16. Epub 2012 Jan 9. Review. PubMed PMID: 22231610.
10. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144(5):326-36.
11. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011;171(3):218-25. PubMed PMID: 21325111; PubMed Central PMCID: PMC3137269.
12. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875-83. Epub 2008 May 27. PubMed PMID: 18506010.
13. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41. Epub 2010 Dec 6. PubMed PMID: 21144578.
14. Chan AT, Cook NR. Are we ready to recommend aspirin for cancer prevention? Lancet. 2012;379(9826):1569-71. Epub 2012 Mar 21. PubMed PMID: 22440945.
15. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007;167(3):290-5.
16. Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural history of prevalent ischaemic heart disease in middleaged men. Eur Heart J. 2000;21(131):1052-62.
17. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24(6):796-800.
18. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(part 2):293-8.
19. Kung HC, Hoyert DL, Xu JQ, Murphy SL. Deaths: Final Data for 2005. National Vital Statistics Reports; vol 56 no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
20. Surveillance, Epidemiology, and End Results Program. SEER Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009. Available at: www.seer.cancer.gov. Accessed on September 8, 2011.
21. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98(7):1494-9.
22. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom: Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222-226.
23. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602-12. Epub 2012 Mar 21. Review. PubMed PMID: 22440946.
24. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. JAMA. 1998;280(22):1930-5.
25. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-6.
26. Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. Health Aff (Millwood). 2004;23(4):176-183.
27. Lubitz J, Cai L, Kramarow E, Lentzner H. Health, life expectancy, and health care spending among the elderly. N Engl J Med. 2003;349(11):1048-1055.
28. U.S. Department of Labor, U.S. Bureau of Labor Statistics, US city average, not seasonally adjusted medical care. http://data.bls.gov/PDQ/outside. jsp?survey=cu. Accessed February 2012.
29. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 Patients. Am J Med. 2012 Jun 27.[Epub ahead of print] PubMed PMID: 22748400.
30. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med. 2002;136(2):61-172.
31. Straube S, Tramèr MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41.
32. www.Walgreens.com, accessed 9Sep11.
33. Ingenix, Inc. The Essential RBRVS (2012): A comprehensive listing of RBRVS values for CPT and HCPCS Codes. St. Anthony Publishing, 2012.
34. HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/HCUPnet/ Accessed 7Mar2012.
35. Friedman B, La Mare J, Andrews R, McKenzie DH. Assuming an average cost to charge ratio of 0.5: practical options for estimating cost of hospital inpatient stays. J Health Care Finance. 2002;29(1):1-13.
36. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81(9):1110-5.
37. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2011;123(4):e18-e209.
38. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: A population-based study. Neurology. 1996;46(3):1-13.
39. Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008;24(2):461-468.
40. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13(12):824-35.
41. Nease RF, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA. 1995;273(5):1185-90.
42. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al. Stroke after thrombolysis: mortaltiy and functional outcomes in the GUSTO-I trial. Circulation. 1995;92(10):2811-8.
43. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13(2):161-5.